Can supervise: YES
Ren, B, La, QT, O'Brien, BA, Nassif, NT, Tan, Y, Gerace, D, Martiniello-Wilks, R, Torpy, F, Dane, AP, Alexander, IE & Simpson, AM 2018, 'Partial pancreatic transdifferentiation of primary human hepatocytes in the livers of a humanised mouse model.', The journal of gene medicine, vol. 20, no. 5, p. e3017.View/Download from: UTS OPUS or Publisher's site
Gene therapy is one treatment that may ultimately cure type 1 diabetes. We have previously shown that the introduction of furin-cleavable human insulin (INS-FUR) to the livers in several animal models of diabetes resulted in the reversal of diabetes and partial pancreatic transdifferentiation of liver cells. The present study investigated whether streptozotocin-diabetes could be reversed in FRG mice in which chimeric mouse-human livers can readily be established and, in addition, whether pancreatic transdifferentiation occurred in the engrafted human hepatocytes.Engraftment of human hepatocytes was confirmed by measuring human albumin levels. Following delivery of the empty vector or the INS-FUR vector to diabetic FRG mice, mice were monitored for weight and blood glucose levels. Intraperitoneal glucose tolerance tests (IPGTTs) were performed. Expression levels of pancreatic hormones and transcription factors were determined by a reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry.Diabetes was reversed for a period of 60 days (experimental endpoint) after transduction with INS-FUR. IPGTTs of the insulin-transduced animals were not significantly different from nondiabetic animals. Immunofluorescence microscopy revealed the expression of human albumin and insulin in transduced liver samples. Quantitative RT-PCR showed expression of human and mouse endocrine hormones and -cell transcription factors, indicating partial pancreatic transdifferentiation of mouse and human hepatocytes. Nonfasting human C-peptide levels were significantly higher than mouse levels, suggesting that transdifferentiated human hepatocytes made a significant contribution to the reversal of diabetes.These data show that human hepatocytes can be induced to undergo partial pancreatic transdifferentiation in vivo, indicating that the technology holds promise for the treatment of type 1 diabetes.
Gerace, D, Martiniello-Wilks, R, Nassif, NT, Lal, S, Steptoe, R & Simpson, AM 2017, 'CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success?', Stem cell research & therapy, vol. 8, no. 1, p. 62.View/Download from: UTS OPUS or Publisher's site
Due to their ease of isolation, differentiation capabilities, and immunomodulatory properties, the therapeutic potential of mesenchymal stem cells (MSCs) has been assessed in numerous pre-clinical and clinical settings. Currently, whole pancreas or islet transplantation is the only cure for people with type 1 diabetes (T1D) and, due to the autoimmune nature of the disease, MSCs have been utilised either natively or transdifferentiated into insulin-producing cells (IPCs) as an alternative treatment. However, the initial success in pre-clinical animal models has not translated into successful clinical outcomes. Thus, this review will summarise the current state of MSC-derived therapies for the treatment of T1D in both the pre-clinical and clinical setting, in particular their use as an immunomodulatory therapy and targets for the generation of IPCs via gene modification. In this review, we highlight the limitations of current clinical trials of MSCs for the treatment of T1D, and suggest the novel clustered regularly interspaced short palindromic repeat (CRISPR) gene-editing technology and improved clinical trial design as strategies to translate pre-clinical success to the clinical setting.
Lees, T, Nassif, N, Simpson, A, Shad-Kaneez, F, Martiniello-Wilks, R, Lin, Y, Jones, A, Qu, X & Lal, S 2017, 'Recent advances in molecular biomarkers for diabetes mellitus: a systematic review.', Biomarkers, vol. 22, no. 7, pp. 604-613.View/Download from: UTS OPUS or Publisher's site
CONTEXT: Diabetes is a growing global metabolic epidemic. Current research is focussing on exploring how the biological processes and clinical outcomes of diabetes are related and developing novel biomarkers to measure these relationships, as this can subsequently improve diagnostic, therapeutic and management capacity. OBJECTIVE: The objective of this study is to identify the most recent advances in molecular biomarkers of diabetes and directions that warrant further research. METHODS: Using a systematic search strategy, the MEDLINE, CINAHL and OVID MEDLINE databases were canvassed for articles that investigated molecular biomarkers for diabetes. Initial selections were made based on article title, whilst final inclusion was informed by a critical appraisal of the full text of each article. RESULTS: The systematic search returned 246 records, of which 113 were unique. Following screening, 29 records were included in the final review. Three main research strategies (the development of novel technologies, broad biomarker panels, and targeted approaches) identified a number of potential biomarkers for diabetes including miR-126, C-reactive protein, 2-aminoadipic acid and betatrophin. CONCLUSION: The most promising research avenue identified is the detection and quantification of micro RNA. Further, the utilisation of functionalised electrodes as a means to detect biomarker compounds also warrants attention.
Ren, B, Tao, C, Swan, MA, Joachim, N, Martiniello-Wilks, R, Nassif, NT, O'Brien, BA & Simpson, AM 2016, 'Pancreatic Transdifferentiation and Glucose-Regulated Production of Human Insulin in the H4IIE Rat Liver Cell Line', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 17, no. 4.View/Download from: UTS OPUS or Publisher's site
Gerace, D, Martiniello-Wilks, R & Simpson, AM 2015, 'Diabetes reversal via gene transfer: building on successes in animal models', Research and Reports in Endocrine Disorders, vol. 5, pp. 15-29.View/Download from: UTS OPUS or Publisher's site
Type 1 diabetes (T1D) is caused by the autoimmune destruction of the insulin-producing pancreatic -cells. People with T1D manage their hyperglycemia using daily insulin injections; however, this does not prevent the development of long-term diabetic complications such as retinopathy, nephropathy, neuropathy, and various macrovascular disorders. Currently, the only "cure" for T1D is pancreas transplantation or islet-cell transplantation; however, this is hampered by the limited number of donors and the requirement for life-long immunosuppression. As a result, the need for alternative therapies is vital. One of the strategies employed to correct T1D is the use of gene transfer to generate the production of an 'artificial -cell that is capable of secreting insulin in response to fluctuating glucose concentrations that normally occurs in people without T1D. The treatment of many diseases using cell and gene therapy is generating significant attention in the T1D research community; however, for a cell therapy to enter clinical trials, success and safety must first be shown in an appropriate animal model. Animal models have been used in diabetes research for over a century, have improved our understanding of the pathophysiology of diabetes, and have led to the discovery of useful drugs for the treatment of the disease. Currently, the nonobese diabetic mouse is the animal model of choice for the study of T1D as it most closely reflects disease development in humans. The aim of this review is to evaluate the success of cell and gene therapy to reverse T1D in animal models for future clinical application.
Gerace, D, Martiniello-Wilks, R, O'Brien, BA & Simpson, AM 2015, 'The use of beta-cell transcription factors in engineering artificial beta cells from non-pancreatic tissue', GENE THERAPY, vol. 22, no. 1, pp. 1-8.View/Download from: UTS OPUS or Publisher's site
Yagoub, D, Wilkins, MR, Lay, AJ, Kaczorowski, DC, Hatoum, D, Bajan, S, Hutvagner, G, Lai, JH, Wu, W, Martiniello-Wilks, R, Xia, P & McGowan, EM 2014, 'Sphingosine Kinase 1 Isoform-Specific Interactions in Breast Cancer', MOLECULAR ENDOCRINOLOGY, vol. 28, no. 11, pp. 1899-1915.View/Download from: UTS OPUS or Publisher's site
Nield, B.S., Guzowski, R., Nassif, N., Simpson, A.M. & Martiniello-Wilks, R. 2014, 'First use of Re: View: A tool to combine assessment tasks, marking criteria and graduate attributes for biochemistry students', International Journal of Innovation in Science and Mathematics Education, vol. 22, no. 7, pp. 49-64.View/Download from: UTS OPUS
In order to improve clarity of the link between assessment tasks and graduate attributes to students, Re:View was introduced across three undergraduate biochemistry subjects. Re:View is an online assessment tool which provides a direct visual link between graduate attributes and marking criteria. It also provides students with an easy access portal to retrieve their grade and assessor feedback on assessment tasks. Our aim was to improve the second and third year biochemistry student laboratory-based learning experience by developing and clarifying the link between assessment tasks, marking criteria and graduate attributes, using Re:View as the assessment tool. Student opinion showed Re:View was of benefit to align marking criteria with graduate attributes, and provided easy access to feedback which could be used to improve future work. This first use of Re:View, with development of criterion-referenced marking criteria and rubrics, has revolutionised assessment in the three biochemistry subjects under study. With the use of Re:View we have clarified the link between assessment tasks and marking criteria, and enhanced student engagement with laboratory-based assessment tasks, which has improved their written assessment performance.
Martiniello-Wilks, R, Suurbach, JH, Tran, N, Mcgowan, EM, Simpson, A, Larsen, SR & Russell, PJ 2012, 'Cellular and genetic medicines advancing the treatment of prostate cancer', JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, vol. 6, pp. 289-289.
McGowan, EM, Tran, NT, Alling, N, Yagoub, D, Sedger, LM & Martiniello-Wilks, R 2012, 'P14ARF Post-transcriptional Regulation Of Nuclear Cyclin D1 In Mcf-7 Breast Cancer Cells: Discrimination Between A Good And Bad Prognosis?', Plos One, vol. 7, no. 7, pp. 1-16.View/Download from: UTS OPUS or Publisher's site
As part of a cell's inherent protection against carcinogenesis, p14ARF is upregulated in response to hyperproliferative signalling to induce cell cycle arrest. This property makes p14ARF a leading candidate for cancer therapy. This study explores the con
Suurbach, JH, McGowan, EM, Simpson, A, Tran, N & Martiniello-Wilks, R 2012, 'A unique bioluminescent prostate cancer mouse model for the evaluation of stem-cell based gene therapy', JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE, vol. 6, pp. 288-288.
McGowan, EM, Alling, N, Jackson, E, Yagoub, D, Haass, NK, Allen, J & Martiniello-Wilks, R 2011, 'Evaluation Of Cell Cycle Arrest In Estrogen Responsive MCF-7 Breast Cancer Cells: Pitfalls Of The MTS Assay', PLoS ONE, vol. 6, no. 6, pp. 0-0.View/Download from: UTS OPUS or Publisher's site
Endocrine resistance is a major problem with anti-estrogen treatments and how to overcome resistance is a major concern in the clinic. Reliable measurement of cell viability, proliferation, growth inhibition and death is important in screening for drug t
Tang, C, Russell, P, Martiniello-Wilks, R, Rasko, J & Khatri, A 2010, 'Concise Review: Nanoparticles And Cellular Carriers-Allies In Cancer Imaging And Cellular Gene Therapy?', Stem Cells, vol. 28, no. 9, pp. 1686-1702.View/Download from: UTS OPUS or Publisher's site
Ineffective treatment and poor patient management continue to plague the arena of clinical oncology. The crucial issues include inadequate treatment efficacy due to ineffective targeting of cancer deposits, systemic toxicities, suboptimal cancer detectio
Khatri, A, Tang, C, Verma, N, Yuan, Z, Wang, X, Martiniello-Wilks, R, Rasko, JEJ, Thierry, B & Russell, PJ 2009, 'NANOTECHNOLOGY AND MESENCHYMAL STEM CELLS - PROSPECTS IN CANCER IMAGING AND GENETHERAPY?', JOURNAL OF GENE MEDICINE, vol. 11, no. 9, pp. 854-854.
Martiniello-Wilks, R, O'Han, M, Meyers, G, Randall, JM, Larsen, SR & Rasko, JEJ 2009, 'ADULT STEM-CELL BASED DELIVERY OF A PROSTATE CANCER GENE THERAPY', JOURNAL OF GENE MEDICINE, vol. 11, no. 9, pp. 842-842.
O'Han, M, Meyers, G, Rasko, JEJ & Martiniello-Wilks, R 2009, 'NUCLEOFECTION IS AN EFFICIENT METHOD FOR THE GENETIC MODIFICATION OF MURINE MESENCHYMAL STEM CELLS', JOURNAL OF GENE MEDICINE, vol. 11, no. 9, pp. 848-848.
Larsen, S, Chng, K, Battah, F, Martiniello-Wilks, R & Rasko, J 2008, 'Improved granulocyte colony-stimulating factor mobilization of hemopoietic progenitors using cytokine combinations in primates', Stem Cells, vol. 26, no. 11, pp. 2974-2980.View/Download from: UTS OPUS or Publisher's site
Peripheral blood stem cells (PBSCs), usually mobilized with granulocyte colony-stimulating factor (G-CSF) alone or in combination with chemotherapy, are the preferred source of cells for hemopoietic stem cell transplantation. Up to 25% of otherwise eligi
Chng, K, Larsen, S, Zhou, S, Wright, JJ, Martiniello-Wilks, R & Rasko, J 2007, 'Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cells', Journal Of Gene Medicine, vol. 9, no. 1, pp. 22-32.View/Download from: UTS OPUS or Publisher's site
Mesenchymal stromal cells (MSCs) show great promise for ex vivo gene and cell-mediated therapies. The immunophenotype and in vitro differentiation capacity of primary baboon MSCs was demonstrated to be near-identical to that observed in human MSCs. To op
The expansion of human cells to produce cell therapeutic products for the treatment of disease is, with few exceptions, an experimental therapy. Because cell therapies involve a biological product, often with some genetic or other modification, they requ
Khatri, A, Zhang, B, Doherty, E, Chapman, JC, Ow, K, Pwint, H, Martiniello-Wilks, R & Russell, P 2006, 'Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice', Journal Of Gene Medicine, vol. 8, no. 9, pp. 1086-1096.View/Download from: UTS OPUS or Publisher's site
Background We aimed to evaluate the efficacy of gene-directed enzyme-prodrug therapy (GDEPT) using cytosine deaminase in combination with uracil phosphoribosyl transferase (CDUPRT) against intraprostatic mouse androgen-refractory prostate (RM1) tumors in
Larsen, SR, Chng, K, Zhou, S, Wright, J, Armstrong, M, Thompson, S, Hennessy, A, Martiniello-Wilks, R, Gibson, J, Joshua, DE & Rasko, JEJ 2006, 'Optimizing mobilization, augmentation, and gene transfer of multipotent mesenchymal stromal cells (MSCs).', BLOOD, vol. 108, no. 11, pp. 722A-723A.
Martiniello-Wilks, R, Dane, A, Voeks, D, Jeyakumar, G, Mortensen, E, Shaw, J, Wang, X, Both, G & Russell, P 2004, 'Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease', Journal Of Gene Medicine, vol. 6, no. 1, pp. 43-54.View/Download from: UTS OPUS or Publisher's site
Background Gene-directed enzyme prodrug therapy (GDEPT) based on the E. coli enzyme purine nucleoside phosphorylase (PNP) represents a new approach for treating slow growing tumours like prostate cancer (PCa). Expressed enzyme converts a systemically adm
Martiniello-Wilks, R, Wang, X, Voeks, D, Dane, A, Shaw, J, Mortensen, E, Both, G & Russell, P 2004, 'Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer', Journal Of Gene Medicine, vol. 6, no. 12, pp. 1343-1357.View/Download from: UTS OPUS or Publisher's site
Gene-directed enzyme prodrug therapy based on the E. coli purine nucleoside phosphorylase (PNP) gene produces efficient tumour cell killing. PNP converts adenosine analogs into toxic metabolites that diffuse across cell membranes to kill neighbouring unt
Russell, P, Ow, K, Tam, P, Juarez, J, Kingsley, E, Qu, C, Li, Y, Cozzi, P & Martiniello-Wilks, R 2004, 'Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer', Cancer Immunology Immunotherapy, vol. 53, no. 11, pp. 995-1004.View/Download from: UTS OPUS or Publisher's site
Background: Monoclonal antibodies (MAbs) can be used to detect, image and treat cancers. This study aimed to characterise the binding of BLCA-38 MAbs to human prostate cancer cell lines, human prostate cancer biopsy samples and normal tissues to enable f
Wang, X, Martiniello-Wilks, R, Shaw, J, Ho, T, Coulston, N, Cooke-yarborough, C, Molloy, P, Cameron, F, Moghaddam, M, Lockett, T, Webster, L, Smith, I, Both, G & Russell, P 2004, 'Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus', Gene Therapy, vol. 11, no. 21, pp. 1559-1567.View/Download from: UTS OPUS or Publisher's site
Gene-directed enzyme prodrug therapy (GDEPT) based on the Escherichia coli enzyme, purine nucleoside phosphorylase (PNP), provides a novel strategy for treating slowly growing tumors like prostate cancer (CaP). PNP converts systemically administered prod
Martiniello-Wilks, R, Dane, A, Mortensen, E, Jeyakumar, G, Wang, X & Russell, P 2003, 'Application Of The Transgenic Adenocarcinoma Mouse Prostate (Tramp) Model For Pre-Clinical Therapeutic Studies', Anticancer Research, vol. 23, no. 3B, pp. 2633-2642.
Background: The suitability of (C57BL/6 TRAMP x C57BL/6)F1 transgenic (TRAMP+) mice with well-to moderately-differentiated prostate cancer (PCa) was assessed for pre-clinical therapeutic studies. Materials and Methods: TRAMP+ and TRAMP- mice were assesse
Martiniello-Wilks, R, Dane, A, Mortensen, E, Jeyakumar, G, Wang, XY & Russell, PJ 2003, 'Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies', Anticancer Research, vol. 23, no. 3 B, pp. 2633-2642.
Background: The suitability of (C57BL/6 TRAMP x C57BL/6)F1 transgenic (TRAMP+) mice with well-to moderately-differentiated prostate cancer (PCa) was assessed for pre-clinical therapeutic studies. Materials and Methods: TRAMP+ and TRAMP- mice were assessed for variability in genitourinary tract weight, seminal vesicle weight, prostate weight/volume and histopathology. Time-points included the reported ages of average tumour onset (25 weeks) and PCa-induced death (33 weeks). Results: Seventy % of TR4MP+ mice aged 25-33 weeks had well-to moderately-differentiated PCa. At 25-28 weeks, the mean genitourinary tract weight was 2X greater and the mean prostate weight/volume was 1.5X more in TRAMP+ than in TRAMP- mice, respectively. Prostate weight/volume showed significant increases (p<0.0001) by 2X and 3X, respectively by 31-33 weeks of age. Conclusion: The window for using the TRAMP model successfully for pre-clinical experimentation is 25-33 weeks provided that mice with poorly-differentiated PCa showing a large tumour burden are excluded.
Martiniello-Wilks, R, Tsatralis, T, Russell, P, Brookes, DE, Zandvliet, D, Lockett, L, Both, G, Molloy, P & Russell, P 2002, 'Transcription-targeted gene therapy for androgen-independent prostate cancer', Cancer Gene Therapy, vol. 9, no. 5, pp. 443-452.View/Download from: UTS OPUS or Publisher's site
The Escherichia coli enzyme (purine nucleoside phosphorylase, PNP) gene is delivered directly into PC3 tumors by one injection of replication-deficient human type-5 adenovirus (Ad5). Expressed PNP converts the systemically administered prodrug, 6MPDR, to
Voeks, D, Martiniello-Wilks, R & Russell, P 2002, 'Derivation of MPR And TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies', Urological Oncology, vol. 7, no. 3, pp. 111-118.View/Download from: UTS OPUS
Pre-clinical models of primary and metastatic prostate cancer are increasingly needed to evaluate efficacy of the new therapeutic strategies currently under investigation. The androgen-independent RM1 and androgen-dependent TR cell lines derived from tra
Voeks, D, Martiniello-Wilks, R, Madden, V, Smith, K, Bennetts, E, Both, G & Russell, P 2002, 'Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models', Gene Therapy, vol. 9, no. 12, pp. 759-768.View/Download from: UTS OPUS or Publisher's site
A gene-directed enzyme pro-drug therapy (GDEPT) based on purine nucleoside phosphorylase (PNP), that converts the prodrug, fludarabine to 2-fluoroadenine, has been described, but studies are limited compared with other GDEPTs. We investigated the in vitr
Voeks, D, Martiniello-Wilks, R, Madden, V, Smith, K, Bennetts, E, Both, GW & Russell, PJ 2002, 'Is a small Monte Carlo analysis a good analysis? Checking the size, power and consistency of a simulation-based test', Statistical Papers, vol. 43, no. 4, pp. 567-577.View/Download from: Publisher's site
In this paper we study the relationship between the number of replications and the accuracy of the estimated quantiles of a distribution obtained by simulation. A method for testing hypotheses on the quantiles of a theoretical distribution using the simulated distribution is proposed, as well as a method to check the hypothesis of consistency of a test.
Martiniello-Wilks, R, Garcia-aragon, J, Daja, M, Russell, P, Both, G, Molloy, P, Lockett, L & Russell, P 1998, 'In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors', Human Gene Therapy, vol. 9, no. 11, pp. 1617-1626.View/Download from: UTS OPUS or Publisher's site
Advanced prostate cancer is invariably lethal once it becomes androgen independent (AI). With the aim of developing a new treatment we have used the human androgen-independent prostate cancer cell line, PC-3, to evaluate the effectiveness of two enzyme-d
Russell, P., Martiniello-Wilks, R., Lockett, L., Brookes, D.E., Zandvliet, D., Watt, F., Molloy, P., Khatri, A. & Both, G. 1998, 'Prostate cancer gene therapy', Australasian Biotechnology, vol. 8, no. 2, pp. 99-106.View/Download from: UTS OPUS
Recent developments in molecular biology have provided the opportunity for new gene therapy-based approaches for treating prostate cancer. A range of approaches are being taken for different cancer types, with over a hundred clinical trials of gene thera
Martiniello, R, Burton, RC & Smart, YC 1997, 'Natural cell-mediated cytotoxicity (NCMC) against NK-sensitive tumours in vitro by murine spleen Ly-6C+ natural T cells.', International journal of cancer, vol. 70, no. 4, pp. 450-460.View/Download from: 3.0.co;2-j">Publisher's site
Ly-6C+ cells constitute 13 +/- 3% of freshly isolated (CBA x C57BL/6)F1 mouse spleen leukocytes. Three distinct populations were identified: CD3 epsilon +NK-1.1- conventional T cells (6%), CD3 epsilon -NK-1.1- granulocytes (5%) and CD3 epsilon +NK-1.1+ T cells (approximately 2%). The CD3 epsilon +NK-1.1+ cells displayed a predominantly large granular leukocyte morphology and were the only Ly-6C+ cell subset identified by MAb 2B6-F2 to spontaneously lyse the NK-sensitive YAC-1 tumour in vitro. On further phenotypic analysis, these cells co-expressed high levels of TCRV beta 8.1/8.2 and CD11b, moderate levels of CD90 and low levels of CD4 or CD8. The removal of CD4+ and CD8+ cells prior to Ly-6C+ cell sorting showed that it was the CD4-CD8- double-negative (DN) CD3 epsilon +NK-1.1+ T-cell subset which was responsible for killing YAC-1. These results indicate that we have identified a DN Ly-6C+ subset of the recently designated NK-1.1+TCR alpha beta low natural T (NT) cells, which are capable of natural cell-mediated cytotoxicity (NCMC) against the NK-sensitive YAC-I tumour in vitro. Additionally, these cells mediated the in vitro killing of 2 further NK-sensitive tumours, murine B16 melanoma and human Jurkat T lymphoma. YAC-1 and Jurkat expressed Fas and were susceptible to anti-Fas MAb or rhuman Fas ligand (rhFasL)-induced lysis. Furthermore, anti-human Fas MAb M3 was shown to block sorted Ly-6C+ splenocyte in vitro killing of Jurkat. In contrast, B16 did not express cell-surface Fas and was resistant to anti-Fas MAb-induced lysis. Taken together, these results show that not only do Ly-6C+ NT cells kill NK-sensitive tumours in vitro but they mediate this activity via multiple cytotoxic mechanisms including Fas.
Martiniello-Wilks, R, Burton, R & Smart, Y 1997, 'Natural cell-mediated cytotoxicity (NCMC) against NK-sensitive tumours in vitro by murine spleen Ly-6C(+) natural T cells', International Journal of Cancer, vol. 70, no. 4, pp. 450-460.View/Download from: UTS OPUS or 3.0.CO;2-J">Publisher's site
Ly-6C(+) cells constitute 13 +/- 3% of freshly isolated (CBA x C57/BL6)F-1 mouse spleen leukocytes. Three distinct populations were identified: CD3 epsilon(+)NK-1.1(-) conventional T cells (6%), CD3 epsilon(-)NK-1.1(-) granulocytes (5%) and CD3 epsilon(+
Martiniello-Wilks, R, Burton, R & Smart, Y 1996, 'Ly-6C(+) natural T (NT) cells mediate immune surveillance against NK-sensitive and NK-resistant transplantable tumours in certain strains of mice', International Journal of Cancer, vol. 66, no. 4, pp. 532-537.View/Download from: UTS OPUS
We have previously shown that anti-Ly-6C monoclonal antibody (MAb) 2B6-F2 identifies a subset of (CBA +/- C57BL/6)F-1 splenic NK-1.1(+) natural T (NT) cells which kill the NK-sensitive YAC-I target in vitro. Furthermore, these Ly-6C(+) cells are responsi
Martiniello-Wilks, R, Smart, Y & Burton, R 1994, 'Monoclonal-Antibody 2B6-F2 Identifies A Subset Of Murine Natural-Killer-Cells With Receptors For YAC-1 And WEHI-164 Targets', Cellular Immunology, vol. 156, no. 1, pp. 155-169.View/Download from: UTS OPUS or Publisher's site
This study reports the generation of rat MoAb 2B6-F2 (IgG2a) that identifies a subpopulation of murine NK cells in the spleen, bone marrow, peripheral blood, lung, and peritoneal leukocytes. By flow cytometry, 2B6-F2 reacted with 10% of naive CBA (immuni
Gerace, D, Martiniello-Wilks, R & Simpson, AM 2016, 'Viral-Mediated Gene Therapy for the Generation of Artificial Insulin-Producing Cells as a Therapeutic Treatment for Type 1 Diabetes Mellitus' in Hardikar, AA (ed), Pancreatic Islet Biology, Springer, Germany, pp. 241-257.View/Download from: UTS OPUS or Publisher's site
Over the past decade, several approaches have been employed to develop cell and gene therapy strategies that generate artificial insulin-producing cells (IPCs) for potential therapeutic applications in the treatment of type 1 diabetes mellitus (T1D) . The genetic engineering of functional IPCs necessitates a broad understanding of the pancreatic developmental process and the cell transcription factors that govern mature cell differentiation and function. To successfully obtain functional IPCs, the type of vectors utilised for gene transfer and the selection of a suitable target cell for subsequent differentiation into IPCs is of fundamental importance. Techniques for manufacturing IPCs include the dedifferentiation and directed transdifferentiation of autologous or allogeneic cells ex vivo followed by transplantation and the in vivo transdifferentiation of target tissue via viral gene transfer. Ultimately, the goal is to construct IPCs that have the capacity to process, store and secrete insulin in response to fluctuating blood glucose levels, whilst avoiding the administration of immunosuppressants and recurrent autoimmune destruction, thereby indefinitely restoring normoglycaemia.
Suurbach, JH, Tan, M, Simpson, AM, Kench, J, Gupta, R & Martiniello-Wilks, R 2017, 'PRECLINICAL EVALUATION OF A BMSC DELIVERED GENE-DIRECTED ENZYME PRO-DRUG THERAPY (GDEPT) LOCAL BYSTANDER EFFECT IN IMMUNE INTACT MOUSE MODELS OF PRIMARY AND METASTATIC PROSTATE CANCER', JOURNAL OF GENE MEDICINE, Joint 10th Annual Scientific Meeting of the Australian-Gene-and-Cell-Therapy-Society (AGCTS) and Australasian-Society-for-Stem-Cell-Research (ASSCR), WILEY, Univ Technol Sydney, Sydney, AUSTRALIA.
Gerace, D, Martiniello-Wilks, R, Nassif, NT, Ren, B & Simpson, AM 2017, 'Ex Vivo Expanded Murine Mesenchymal Stem Cells as Targets for the Generation of a Cell Replacement Therapy for Type 1 Diabetes', DIABETES, 77th Scientific Sessions of the American-Diabetes-Association, AMER DIABETES ASSOC, San Diego, CA, pp. A83-A83.View/Download from: UTS OPUS
Brennan, S, Tran, N, Clayton, A, Webber, J, Cozzi, P & Martiniello-Wilks, R 2015, 'EXOSOMAL MICRORNA: POTENTIAL URINARY AND PLASMA BASED BIOMARKERS FOR THE DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER', JOURNAL OF GENE MEDICINE, pp. 203-204.View/Download from: UTS OPUS
Gerace, D, Martiniello-Wilks, R & Simpson, AM 2015, 'Persistence of Luciferase Expressing Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs) in Non-Obese Diabetic (NOD) and NOD/Scid Mice', MOLECULAR THERAPY, pp. S101-S101.
Gerace, D., Martiniello-Wilks, R. & Simpson, A.M. 2015, 'BIOLUMINESCENT IMAGING OF MESENCHYMAL STEM CELL ENGRAFTMENT IN IMMUNE COMPETENT AND IMMUNE DEFICIENT ANIMAL MODELS OF TYPE 1 DIABETES', JOURNAL OF GENE MEDICINE, pp. 201-201.
Habib, R., Brennan, S., Tan, M., Larsen, S.R. & Martiniello-Wilks, R. 2015, 'UNDERSTANDING AND HARNESSING MESENCHYMAL STEM CELL HOMING TO METASTATIC PROSTATE CANCER', JOURNAL OF GENE MEDICINE, pp. 200-201.View/Download from: UTS OPUS
Suurbach, J.H., Habib, R., Brennan, S., Larsen, S.R., Simpson, A. & Martiniello-Wilks, R. 2015, 'CELLULAR AND GENETIC MEDICINES ADVANCING THE TREATMENT OF METASTATIC PROSTATE CANCER', JOURNAL OF GENE MEDICINE, pp. 198-199.View/Download from: UTS OPUS
Ren, B, O'Brien, BA, Alexander, IE, Nassif, NT, Tan, Y, Martiniello-Wilks, R & Simpson, AM 2015, 'Pancreatic Transdiffereniation of Human Hepatocytes in the Livers of a Humanized Mouse Model', MOLECULAR THERAPY, pp. S110-S110.View/Download from: UTS OPUS
Simpson, A, Ren, B, O'Brien, BA, Alexander, IE, Nassif, NT, Tan, Y & Martiniello-Wilks, R 2015, 'Gene therapy for diabetes: reversal of diabetes in the humanised FRG mouse model', XENOTRANSPLANTATION, pp. S41-S42.View/Download from: UTS OPUS
Simpson, A., Ren, B., O'Brien, B.A., Alexander, I.E., Nassif, N.T., Tan, Y. & Martiniello-Wilks, R. 2015, 'GENE THERAPY FOR DIABETES: REVERSAL OF DIABETES IN THE HUMANISED FRG MOUSE MODEL.', TRANSPLANTATION, pp. S67-S67.View/Download from: UTS OPUS
Brennan, SE, Tran, N, Clayton, A, McGowan, EM, Cozzi, PJ & Martiniello-Wilks, R 2013, 'PROSTATE CANCER EXOSOMES OFFERING NOVEL CIRCULATING BIOMARKERS FOR EARLY CANCER DIAGNOSIS AND PROGNOSIS', JOURNAL OF GENE MEDICINE, pp. 331-332.
Habib, R, McGowan, E, Larsen, SR & Martiniello-Wilks, R 2013, 'CHARACTERISATION OF A PRIMITIVE BONE MARROW DERIVED MESENCHYMAL STEM CELL SUBPOPULATION SHOWING IMPROVED PROSTATE CANCER TROPISM', JOURNAL OF GENE MEDICINE, pp. 333-333.
Nield, BS, Martiniello-Wilks, R, Guzowski, R, Simpson, A & Nassif, N 2013, 'First use of Re:view – a tool to combine assessment tasks, marking criteria and graduate attributes', Australian Conference on Science and Mathematics Education, Canberra, ACT.View/Download from: UTS OPUS
Randall, JM, Tan, M, O'Han, M, Tran, N, Rasko, JEJ, Larsen, SR & Martiniello-Wilks, R 2011, 'ADVANCES IN CELLULAR THERAPEUTIC GENE TRANSFER TARGETING PROSTATE CANCER METASTASES', JOURNAL OF GENE MEDICINE, pp. 421-422.
Tran, N, Zhang, X, Rose, B & Martiniello-Wilks, R 2011, 'CO-REGULATION OF THE PROGRAMMED CELL DEATH PROTEIN 4 (Pdcd4) BY miR-21 and miR-499', JOURNAL OF GENE MEDICINE, pp. 425-426.
Randall, JM, Larsen, SR, Martiniello-Wilks, R & Rasko, JEJ 2009, 'RESTRICTION OF RD114 PSEUDOTYPED VECTORS IN BABOON CD34(+) HSC', JOURNAL OF GENE MEDICINE, pp. 848-849.
Martiniello-Wilks, R, Larsen, SR, Tiffen, JC, Bailey, CG & Rasko, JEJ 2008, 'Cell-based delivery of a prostate cancer suicide gene therapy', HUMAN GENE THERAPY, pp. 401-401.
Martiniello-Wilks, R, Larsen, SR, Tiffen, JC, Bailey, CG & Rasko, JEJ 2007, 'Mesenchymal stem cells as suicide gene therapy vehicles for organ-confined and metastatic prostate cancer (PCa)', BLOOD, pp. 369B-369B.
Martiniello-Wilks, R, Tiffen, J, Bailey, C, Chng, K, Larsen, SR & Rasko, JEJ 2007, 'Mesenchymal stem cells as gene delivery vehicles for cancer gene therapy', JOURNAL OF GENE MEDICINE, pp. 531-531.
Khatri, A, Russell, PJ, Zhang, B, Doherty, E, Ow, K, Chapman, J & Martiniello-Wilks, R 2005, 'Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in C57BL/6 mice', JOURNAL OF GENE MEDICINE, pp. 1129-1130.
Martiniello-Wilks, R, Chng, K, Larsen, SR & Rasko, JEJ 2005, 'Mesenchymal stem cells as gene delivery vehicles for cancer gene therapy', JOURNAL OF GENE MEDICINE, pp. 1129-1129.
Both, GW, Wang, XY, Martiniello-Wilks, R, Dane, A, Molloy, PL, Cameron, FH, Moghaddam, M, Coulston, N, Shaw, JM, Lockett, T, Webster, LK, Smith, IK & Russell, PJ 2003, 'FP253: A prostate targeted gene-directed enzyme prodrug therapy for androgen-sensitive and androgen-independent human prostate cancer', JOURNAL OF GENE MEDICINE, pp. S4-S4.
Martiniello-Wilks, R, Dane, A, Jeyakumar, G, Mortensen, E, Wang, XY, Shaw, JM, Both, GW & Russell, PJ 2003, 'Gene-directed enzyme prodrug therapy (GDEPT) for prostate cancer in a transgenic mouse model that imitates the development of human disease', JOURNAL OF GENE MEDICINE, pp. S4-S4.
Wang, XY, Martiniello-Wilks, R, Dane, A, Ow, KT, Shaw, J, Coulston, N, Both, GW, Smith, IK & Russell, PJ 2003, 'Inhibition of androgen-independent prostate tumour growth and lung metastases following gene-directed enzyme prodrug therapy', JOURNAL OF GENE MEDICINE, pp. S20-S20.